Patents by Inventor Sandra Ross

Sandra Ross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody constructs for CLDN18.2 and CD3
    Patent number: 11692031
    Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 4, 2023
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
  • Bispecific Antibody Construct Directed to MUC17 and CD3
    Publication number: 20210130465
    Abstract: The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and the Macaca CD3E chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 6, 2021
    Inventors: Tobias Raum, Tara Arvedson, Julie Bailis, Christoph Dahlhoff, Sandra Ross, Irwin Chen, Claudia Blümel, Elisabeth Nahrwold, Jochen Pendzialek, Joachim Wahl
  • Antibody Constructs for CLDN18.2 and CD3
    Publication number: 20200055932
    Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 20, 2020
    Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
  • Alerting device and associated method
    Patent number: 8907779
    Abstract: An alerting safety device includes a pole formed from flexible material, a flag attached to the pole, a fastening member attached to a bottom end of the pole, a coupling attached to the fastening member and spaced from the pole, and a light-emitting section attached to a top most end of the pole above the flag. Notably, the light-emitting section is automatically toggled between on and off modes upon receiving input signals respectively.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: December 9, 2014
    Inventor: Sandra Ross
  • Signalling Assay and Cell Line
    Publication number: 20080227131
    Abstract: The invention relates to a sensor for indicating the transduction and inhibition of stress signals through the p38-MAPK pathway in living cells. The sensor comprises a reporter gene product and an isoform of p38 Mitogen Activated Protein Kinase (MAPK). The invention also provides plasmid and viral vectors containing nucleic acids encoding the sensor for the transfection of living cells. Stable cell lines expressing the sensor can be used in a live-cell or fixed-cell assay to measure activation or modulation of the pathway.
    Type: Application
    Filed: October 26, 2006
    Publication date: September 18, 2008
    Applicant: GE HEALTHCARE UK LIMITED
    Inventors: Simon L. J. Stubbs, Catherine Hather, Sandra Ross, David Powers